MELBOURNE, Australia and NEW YORK, Oct. 28, 2013 (GLOBE NEWSWIRE) -- Regenerative medicine company Mesoblast Limited (ASX:MSB) (USOTC:MBLTY) today updated the market on product registration plans in Japan for its proprietary culture-expanded Mesenchymal Stem Cells (MSCs) in the treatment of steroid-refractory graft-versus-host disease (GvHD).
Help employers find you! Check out all the jobs and post your resume.
